Fusion-positive tumours are characterised by frequent amplifications of MDM2, CDK4, EP300, and FRS2, whereas fusion-negative cases are dominated by mutations in TP53, NOTCH1, and related genes. This evidence concerns the gene TP53 and neoplasm.